search
Back to results

A Comparison of Two Initial Dosing Formulas

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Insulin detemir
Sponsored by
Diabetes Care Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring basal insulin, hypoglycemia, diabetes mellitus type two

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Type 2 diabetes
  2. Age 18 years and above
  3. Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ± glinides
  4. A1c ≥ 7.0% but ≤ 10%
  5. Capable of self monitoring glucose ≥4/day
  6. Previously compliant with clinical recommendations
  7. Fasting blood glucose ≥ 150 mg/dl
  8. BMI ≤ 45 kg/m2

Exclusion Criteria:

  1. Urinary ketosis
  2. Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatinine >1.5 mg/dl), glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistant of another)
  3. Currently participating in another clinical trial
  4. Known or suspected allergy to insulin determir
  5. Using insulin
  6. Pregnancy or nursing or the intention of becoming pregnant or not using adequate
  7. Significant liver or heart failure.

Sites / Locations

  • Diabetes Care Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Insulin determir

Arm Description

Outcomes

Primary Outcome Measures

Days to reach the titration target
The number of days for the subject to reach the titration target blood sugar of 110 ml/dl

Secondary Outcome Measures

The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period

Full Information

First Posted
June 17, 2011
Last Updated
August 23, 2013
Sponsor
Diabetes Care Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01377155
Brief Title
A Comparison of Two Initial Dosing Formulas
Official Title
A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabetes Care Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate two methods of starting basal insulin to see which method may achieve a faster-to-goal titration.
Detailed Description
The current recommended starting dose of basal insulin in type 2 diabetes is either a fixed dose, e.g. 10 U, or a weight-based formulas, 0.1-0.2 U/kg. The estimate of eventual titration dose to attempt to reach a fasting glucose goal is 0.49 U/kg. Those many weeks of dosage upward titration are required. The investigators propose to compare the current recommended weight based, 0.1 U/kg to a correction factor derived formula. Starting with an insulin tolerance test estimation of basal dose, one would arrive at the eventual titrated basal insulin dose in significantly less days than starting at a starting dose estimate of 0.1 U/kg. Further, there would be no significant increase in overall reported hypoglycemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
basal insulin, hypoglycemia, diabetes mellitus type two

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin determir
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
Insulin detemir
Intervention Description
Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
Primary Outcome Measure Information:
Title
Days to reach the titration target
Description
The number of days for the subject to reach the titration target blood sugar of 110 ml/dl
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes Age 18 years and above Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ± glinides A1c ≥ 7.0% but ≤ 10% Capable of self monitoring glucose ≥4/day Previously compliant with clinical recommendations Fasting blood glucose ≥ 150 mg/dl BMI ≤ 45 kg/m2 Exclusion Criteria: Urinary ketosis Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatinine >1.5 mg/dl), glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistant of another) Currently participating in another clinical trial Known or suspected allergy to insulin determir Using insulin Pregnancy or nursing or the intention of becoming pregnant or not using adequate Significant liver or heart failure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allen B King, MD
Organizational Affiliation
Diabetes Care Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes Care Center
City
Salinas
State/Province
California
ZIP/Postal Code
93901
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Comparison of Two Initial Dosing Formulas

We'll reach out to this number within 24 hrs